In a filing, Inozyme Pharma Inc revealed its CEO & Chairman Treco Douglas A unloaded Company’s shares for reported $7849.0 on Apr 02 ’25. In the deal valued at $0.89 per share,8,819 shares were sold. As a result of this transaction, Treco Douglas A now holds 41,046 shares worth roughly $44740.14000000001.
Raymond James initiated its Inozyme Pharma Inc [INZY] rating to an Outperform in a research note published on December 12, 2024; the price target was $26. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo started covering the stock on May 30, 2024. It rated INZY as “an Overweight”.
Price Performance Review of INZY
On Tuesday, Inozyme Pharma Inc [NASDAQ:INZY] saw its stock fall -7.63% to $1.09. Over the last five days, the stock has lost -13.49%. Inozyme Pharma Inc shares have fallen nearly -60.65% since the year began. Nevertheless, the stocks have fallen -76.56% over the past one year. While a 52-week high of $6.24 was reached on 01/03/25, a 52-week low of $0.72 was recorded on 04/07/25. SMA at 50 days reached $1.0406, while 200 days put it at $2.9903.
Levels Of Support And Resistance For INZY Stock
The 24-hour chart illustrates a support level at 1.0333, which if violated will result in even more drops to 0.9767. On the upside, there is a resistance level at 1.1633. A further resistance level may holdings at 1.2367. The Relative Strength Index (RSI) on the 14-day chart is 48.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0520, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.84%. Stochastics %K at 22.61% indicates the stock is a holding.
